Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Drug-resistant malaria in Bangui, Central African Republic: An in vitro assessment
American Journal of Tropical Medicine and Hygiene, Volume 73, No. 2, Year 2005
Notification
URL copied to clipboard!
Description
We used an in vitro isotopic drug sensitivity assay to assess the sensitivity of Plasmodium falciparum isolates collected in Bangui, Central African Republic between March and July 2004. We tested antimalarials that are currently in use in this country (chloroquine, amodiaquine, quinine, and pyrimethamine), antimalarials that will become available in this region in the future (artemisinin and halofantrine), and prophylactic antimalarials (mefloquine, doxycycline, and atovaquone). The proportions of resistant isolates were 37% for chloroquine, 15.9% for amodiaquine, 0% for quinine, 0% for dihydroartemisinin, 1.6% for mefloquine, 3.8% for halofantrine, 4.0% for atovaquone, and 38.3% for pyrimethamine. No multi-resistant isolates (showing resistance to more than three drugs) were found. A positive correlation was found between the 50% inhibitory concentrations values for the following drugs: chloroquine and amodiaquine; quinine and halofantrine; chloroquine and dihydroartemisinin; chloroquine and halofantrine; amodiaquine and dihydroartemisinin; dihydroartemisinin and mefloquine; chloroquine and quinine; and quinine and dihydroartemisinin. These findings suggest that the Ministry of Health should recommend a interim policy with the amodiaquine plus sulfadoxine-pyrimethamine combination as the first-line antimalarial drug in Bangui until better alternative treatments such as artemisinin-based combination therapies become available at low prices in the Central African Republic. Copyright © 2005 by The American Society of Tropical Medicine and Hygiene.
Authors & Co-Authors
Menard, Didier
Madagascar, Antananarivo
Institut Pasteur de Madagascar
Djallé, Djibrine
Central African Republic, Bangui
Institut Pasteur de Bangui
Manirakiza, Alexandre
Central African Republic, Bangui
Institut Pasteur de Bangui
Yapou, Ferdinand
Central African Republic, Bangui
Institut Pasteur de Bangui
Siadoua, Valerie
Central African Republic, Bangui
Institut Pasteur de Bangui
Sana, Serge
Central African Republic, Bangui
Institut Pasteur de Bangui
Matsika-Claquin, Marcelle Diane
Central African Republic, Bangui
Institut Pasteur de Bangui
Nestor, Madji
Central African Republic, Bangui
Central African Republic Ministry of Health
Talarmin, Antoine
Central African Republic, Bangui
Institut Pasteur de Bangui
Statistics
Citations: 32
Authors: 9
Affiliations: 3
Identifiers
Doi:
10.4269/ajtmh.2005.73.239
ISSN:
00029637
Research Areas
Health System And Policy
Infectious Diseases
Study Locations
Central African Republic